Lista de obras - Bishal Gyawali - Dominio Público Uruguay

A Systematic Review and Meta-Analysis of Bevacizumab in First-Line Metastatic Breast Cancer: Lessons for Research and Regulatory Enterprises

artículo científico publicado en 2019

A prospective survey of comprehensive score for financial toxicity in Japanese cancer patients: report on a pilot study

artículo científico publicado en 2018

Addressing the Mental Health Challenges of Cancer Care Workers in LMICs During the Time of the COVID-19 Pandemic

artículo científico publicado en 2020

Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials.

artículo científico publicado en 2016

Adoptive cell therapy and modulation of the tumour microenvironment: new insights from ASCO 2016.

artículo científico publicado en 2016

Antifungal prophylaxis with Amphotericin B deoxycholate emulsified in lipids for acute myeloid leukemia patients treated in low economy countries

artículo científico publicado en 2015

Assessing the Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Trials of Cancer Drugs: A Systematic Review and Pooled Analysis

scientific article published on 02 August 2019

Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval

scientific article published on 01 July 2019

Association between age and sex and mortality after adjuvant therapy for renal cancer

scientific article published on 08 January 2019

Association between progression-free survival and patients' quality of life in cancer clinical trials

artículo científico publicado en 2018

Association of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival: A Pooled Analysis

scientific article published on 03 May 2019

Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis

artículo científico publicado en 2018

Bevacizumab in Advanced Cervical Cancer: Issues and Challenges for Low- and Middle-Income Countries.

artículo científico publicado en 2016

Biosimilars in oncology: everybody agrees but nobody uses?

artículo científico publicado en 2017

Breast cancer early detection: A phased approach to implementation

artículo científico publicado en 2020

Cancer care and research in India: what does it mean to Nepal?

artículo científico publicado en 2014

Cancer drugs in LMICs: cheap but unaffordable

artículo científico publicado en 2017

Cancer groundshot: going global before going to the moon

artículo científico publicado en 2018

Cancer treatment in the last 6 months of life: when inaction can outperform action.

artículo científico publicado en 2018

Cheaper Options in the Prevention of Chemotherapy-Induced Nausea and Vomiting

artículo científico publicado en 2016

Chemotherapy in locally advanced head and neck squamous cell carcinoma

artículo científico publicado en 2016

Combining drugs and extending treatment - a PFS end point is not sufficient.

artículo científico publicado en 2017

Continuous versus intermittent docetaxel for metastatic castration resistant prostate cancer.

artículo científico publicado en 2016

Discordance between the results and conclusions of ICON7

artículo científico publicado en 2015

Does Helicobacter pylori eradication therapy to prevent gastric cancer increase all-cause mortality?

scientific article published on 26 October 2018

Does global oncology need artificial intelligence?

artículo científico publicado en 2018

Drugs that lack single-agent activity: are they worth pursuing in combination?

Duration of adjuvant immunotherapy-biologic, clinical and economic considerations

artículo científico publicado en 2018

Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trials

artículo científico publicado en 2017

Economics of Cancer Medicines: For Whose Benefit?

artículo científico publicado en 2017

Efficacy of Prophylactic Treatment for Oxycodone-Induced Nausea and Vomiting Among Patients with Cancer Pain (POINT): A Randomized, Placebo-Controlled, Double-Blind Trial

artículo científico publicado en 2017

Efficacy, Safety, and Regulatory Approval of Food and Drug Administration-Designated Breakthrough and Nonbreakthrough Cancer Medicines

artículo científico publicado en 2018

Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs

scientific article published on 13 April 2020

FDA Approval Summary: Sonidegib-Letter.

artículo científico publicado en 2017

Fall in US cancer death rates: Time to pop the champagne?

scientific article published on 31 January 2020

Financial toxicity of cancer treatment: Moving the discussion from acknowledgement of the problem to identifying solutions

scientific article published on 31 January 2020

Flaws in the trial design of IFCT-0802

artículo científico publicado en 2015

Health policy: Me-too drugs with limited benefits - the tale of regorafenib for HCC.

artículo científico publicado en 2017

Human Trafficking in Nepal: Post-Earthquake Risk and Response.

artículo científico publicado en 2016

Immunotherapy in Non-Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence

scientific article published on 17 April 2019

Information Transparency in the Drug Approval Process-Reply

scientific article published on 01 November 2018

Inspiration amidst the challenges: the first report of successful bone marrow transplantation in the Himalayan country Nepal

artículo científico publicado en 2015

Interpretation of Time-to-event Outcomes in Randomized Trials: an online randomized experiment

artículo científico publicado en 2019

Ischemic Stroke and Impact of Thyroid Profile at Presentation: A Systematic Review and Meta-analysis of Observational Studies.

artículo científico publicado en 2017

Low skeletal muscle density is associated with poor survival in patients who receive chemotherapy for metastatic gastric cancer.

artículo científico publicado en 2015

Low-value practices in oncology contributing to financial toxicity

artículo científico publicado en 2017

Making adjuvant therapy decisions with uncertain data

artículo científico publicado en 2019

Me too-drugs with limited benefits - the tale of regorafenib for HCC.

artículo científico publicado en 2017

Me, Too

artículo científico publicado en 2016

Multiple Approvals, Celestial Prices, Unimproved Outcomes: The Tale of Cost-Ineffective Drugs in Hepatocellular Carcinoma

scientific article published on 01 June 2019

Muscle wasting associated with the long-term use of mTOR inhibitors

artículo científico publicado en 2016

Negative phase 3 randomized controlled trials: Why cancer drugs fail the last barrier?

artículo científico publicado en 2018

Negative trials in ovarian cancer: is there such a thing as too much optimism?

artículo científico publicado en 2016

Opioid-induced constipation.

artículo científico publicado en 2015

Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials

scientific article published on 20 September 2018

Outcomes of haploidentical transplant compared with matched donor allogeneic stem cell transplant.

artículo científico publicado en 2016

Patient-Centered Cancer Drug Development: Clinical Trials, Regulatory Approval, and Value Assessment

artículo científico publicado en 2019

Pazopanib monotherapy in a patient with a malignant granular cell tumor originating from the right orbit: A case report

artículo científico publicado en 2015

Pemetrexed in Nonsquamous Non-Small-Cell Lung Cancer: The Billion Dollar Subgroup Analysis.

artículo científico publicado en 2017

Plasma vs Tissue Next-Generation Sequencing in Non-Small Cell Lung Cancer-Either, Both, or Neither?

artículo científico publicado en 2019

Point: The Imprecise Pursuit of Precision Medicine: Are Biomarkers to Blame?

artículo científico publicado en 2017

Prevalence and correlates of psychological distress symptoms among patients with substance use disorders in drug rehabilitation centers in urban Nepal: a cross-sectional study.

artículo científico publicado en 2016

Prevalence of type 2 diabetes in Nepal: a systematic review and meta-analysis from 2000 to 2014

artículo científico publicado en 2015

Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review

artículo científico publicado en 2017

Prophylactic Use of Antiemetics for Prevention of Opioid-Induced Nausea and Vomiting: A Questionnaire Survey among Japanese Physicians.

artículo científico publicado en 2015

Prospective Survey of Financial Toxicity Measured by the Comprehensive Score for Financial Toxicity in Japanese Patients With Cancer.

artículo científico publicado en 2019

ReDO_DB: the repurposing drugs in oncology database

artículo científico publicado en 2018

Reinforcing the social compromise of accelerated approval

scientific article published on 01 October 2018

Reporting harms more transparently in trials of cancer drugs

artículo científico publicado en 2018

Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis

artículo científico publicado en 2021

Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials†.

artículo científico publicado en 2016

Rushing will not help to choose the best combination

artículo científico publicado en 2017

Safety and Efficacy of Azathioprine as a Second Line Therapy for Primary Immune Thrombocytopenic Purpura.

artículo científico publicado en 2016

Same Data; Different Interpretations

artículo científico publicado en 2016

Should low-income countries invest in breast cancer screening?

artículo científico publicado en 2016

Socioeconomic and health system factors associated with lower utilization of hematopoietic cell transplantation in older patients with acute myeloid leukemia.

artículo científico publicado en 2018

Some questions on the randomized controlled trial of communication skills training for oncologists

artículo científico publicado en 2014

Survival of patients with metastatic breast cancer with or without locoregional therapy

TKI-induced pure red cell aplasia: first case report of pure red cell aplasia with both imatinib and nilotinib.

artículo científico publicado en 2016

The OlympiAD trial: who won the gold?

artículo científico publicado en 2017

The US Food and Drug Administration's Approval of Adjuvant Sunitinib for Renal Cell Cancer: A Case of Regulatory Capture?

artículo científico publicado en 2018

The promise of ESCAT: a new system for evaluating cancer drug-target pairs

article

Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real-World Practice

scientific article published on 03 April 2019

US Food and Drug Administration Approval of New Drugs Based on Noninferiority Trials in Oncology: A Dangerous Precedent?

artículo científico publicado en 2019

Unconvincing Benefit of Combination Therapy With Gefitinib and Pemetrexed in Advanced Non-Small-Cell Lung Cancer

artículo científico publicado en 2016

Use of donated clotting factors for surgeries on haemophilic patients in a resource-constrained country: a kind donor, good outcome, change of practice and future directions

artículo científico publicado en 2016

What Global Oncology Needs: Mutual Learning and More Funding.

artículo científico publicado en 2018

Lista de obras de Bishal Gyawali

A Systematic Review and Meta-Analysis of Bevacizumab in First-Line Metastatic Breast Cancer: Lessons for Research and Regulatory Enterprises

A prospective survey of comprehensive score for financial toxicity in Japanese cancer patients: report on a pilot study

Addressing the Mental Health Challenges of Cancer Care Workers in LMICs During the Time of the COVID-19 Pandemic

Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials.

Adoptive cell therapy and modulation of the tumour microenvironment: new insights from ASCO 2016.

Antifungal prophylaxis with Amphotericin B deoxycholate emulsified in lipids for acute myeloid leukemia patients treated in low economy countries

Assessing the Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Trials of Cancer Drugs: A Systematic Review and Pooled Analysis

Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval

Association between age and sex and mortality after adjuvant therapy for renal cancer

Association between progression-free survival and patients' quality of life in cancer clinical trials

Association of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival: A Pooled Analysis

Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis

Bevacizumab in Advanced Cervical Cancer: Issues and Challenges for Low- and Middle-Income Countries.

Biosimilars in oncology: everybody agrees but nobody uses?

Breast cancer early detection: A phased approach to implementation

Cancer care and research in India: what does it mean to Nepal?

Cancer drugs in LMICs: cheap but unaffordable

Cancer groundshot: going global before going to the moon

Cancer treatment in the last 6 months of life: when inaction can outperform action.

Cheaper Options in the Prevention of Chemotherapy-Induced Nausea and Vomiting

Chemotherapy in locally advanced head and neck squamous cell carcinoma

Combining drugs and extending treatment - a PFS end point is not sufficient.

Continuous versus intermittent docetaxel for metastatic castration resistant prostate cancer.

Discordance between the results and conclusions of ICON7

Does Helicobacter pylori eradication therapy to prevent gastric cancer increase all-cause mortality?

Does global oncology need artificial intelligence?

Drugs that lack single-agent activity: are they worth pursuing in combination?

Duration of adjuvant immunotherapy-biologic, clinical and economic considerations

Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trials

Economics of Cancer Medicines: For Whose Benefit?

Efficacy of Prophylactic Treatment for Oxycodone-Induced Nausea and Vomiting Among Patients with Cancer Pain (POINT): A Randomized, Placebo-Controlled, Double-Blind Trial

Efficacy, Safety, and Regulatory Approval of Food and Drug Administration-Designated Breakthrough and Nonbreakthrough Cancer Medicines

Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs

FDA Approval Summary: Sonidegib-Letter.

Fall in US cancer death rates: Time to pop the champagne?

Financial toxicity of cancer treatment: Moving the discussion from acknowledgement of the problem to identifying solutions

Flaws in the trial design of IFCT-0802

Health policy: Me-too drugs with limited benefits - the tale of regorafenib for HCC.

Human Trafficking in Nepal: Post-Earthquake Risk and Response.

Immunotherapy in Non-Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence

Information Transparency in the Drug Approval Process-Reply

Inspiration amidst the challenges: the first report of successful bone marrow transplantation in the Himalayan country Nepal

Interpretation of Time-to-event Outcomes in Randomized Trials: an online randomized experiment

Ischemic Stroke and Impact of Thyroid Profile at Presentation: A Systematic Review and Meta-analysis of Observational Studies.

Low skeletal muscle density is associated with poor survival in patients who receive chemotherapy for metastatic gastric cancer.

Low-value practices in oncology contributing to financial toxicity

Making adjuvant therapy decisions with uncertain data

Me too-drugs with limited benefits - the tale of regorafenib for HCC.

Me, Too

Multiple Approvals, Celestial Prices, Unimproved Outcomes: The Tale of Cost-Ineffective Drugs in Hepatocellular Carcinoma

Muscle wasting associated with the long-term use of mTOR inhibitors

Negative phase 3 randomized controlled trials: Why cancer drugs fail the last barrier?

Negative trials in ovarian cancer: is there such a thing as too much optimism?

Opioid-induced constipation.

Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials

Outcomes of haploidentical transplant compared with matched donor allogeneic stem cell transplant.

Patient-Centered Cancer Drug Development: Clinical Trials, Regulatory Approval, and Value Assessment

Pazopanib monotherapy in a patient with a malignant granular cell tumor originating from the right orbit: A case report

Pemetrexed in Nonsquamous Non-Small-Cell Lung Cancer: The Billion Dollar Subgroup Analysis.

Plasma vs Tissue Next-Generation Sequencing in Non-Small Cell Lung Cancer-Either, Both, or Neither?

Point: The Imprecise Pursuit of Precision Medicine: Are Biomarkers to Blame?

Prevalence and correlates of psychological distress symptoms among patients with substance use disorders in drug rehabilitation centers in urban Nepal: a cross-sectional study.

Prevalence of type 2 diabetes in Nepal: a systematic review and meta-analysis from 2000 to 2014

Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review

Prophylactic Use of Antiemetics for Prevention of Opioid-Induced Nausea and Vomiting: A Questionnaire Survey among Japanese Physicians.

Prospective Survey of Financial Toxicity Measured by the Comprehensive Score for Financial Toxicity in Japanese Patients With Cancer.

ReDO_DB: the repurposing drugs in oncology database

Reinforcing the social compromise of accelerated approval

Reporting harms more transparently in trials of cancer drugs

Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis

Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials†.

Rushing will not help to choose the best combination

Safety and Efficacy of Azathioprine as a Second Line Therapy for Primary Immune Thrombocytopenic Purpura.

Same Data; Different Interpretations

Should low-income countries invest in breast cancer screening?

Socioeconomic and health system factors associated with lower utilization of hematopoietic cell transplantation in older patients with acute myeloid leukemia.

Some questions on the randomized controlled trial of communication skills training for oncologists

Survival of patients with metastatic breast cancer with or without locoregional therapy

TKI-induced pure red cell aplasia: first case report of pure red cell aplasia with both imatinib and nilotinib.